Mirikizumab Sustains Four-Year Remission in Ulcerative Colitis Responders
This open-label extension confirms durable multi-domain remission with mirikizumab through four years in ulcerative colitis patients who responded by week 52, including prior biologic failures.
📅 Journal publication: Dec 2026(online Jul 7, 2026)·Last updated: Oct 13, 2026
Provider training can drive HPV vaccine uptake in young adults.
HPV vaccination rates are low among US young adults, and provider recommendation is crucial for improving uptake. Fifteen primary care providers found the training helpful, suggesting flexibility and incentives might increase participation. The study highlights the need for effective provider training but is small and preliminary; further testing is required. Enhancing provider training on HPV recommendations may boost vaccination rates among young adults.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Owens HN, Vázquez-Otero C, Arevalo M, Cui J, Chavez M, Maconi ML, Geiss C, Turner K, Vadaparampil ST, Barrios-Monroy V, Pena A, Whiting J, Christy SM
Citation:Owens HN, Vázquez-Otero C, Arevalo M, et al. Development of a theory-based provider-focused training to improve HPV vaccine recommendations for young adults. Human vaccines & immunotherapeutics. 2026;22(1):2679382. doi:10.1080/21645515.2026.2679382
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.